

Katerina Jarosova

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4777650/katerina-jarosova-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22
papers

1,004
citations

10
h-index

23
g-index

23
ext. papers

1,164
ext. citations

6.4
avg. IF

3.12
L-index

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 22 | Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. <i>New England Journal of Medicine</i> , 2008 , 359, 810-20 | 59.2 | 439 |
| 21 | The role of MRI in the assessment of polymyositis and dermatomyositis. <i>Rheumatology</i> , 2007 , 46, 1174-9 | 3.9 | 149 |
| 20 | The importance of cell surface RANKL in rheumatoid arthritis. <i>Arthritis Research</i> , 2005 , 7, P152 | | 78 |
| 19 | Tumour necrosis factor alpha G-->A -238 and G-->A -308 polymorphisms in juvenile idiopathic arthritis. <i>Rheumatology</i> , 2002 , 41, 223-7 | 3.9 | 64 |
| 18 | Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. <i>Annals of the Rheumatic Diseases</i> , 2009 , 68, 1285-9 | 2.4 | 49 |
| 17 | A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 96-102 | 2.4 | 47 |
| 16 | A longitudinal PRINTO study on growth and puberty in juvenile systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2012 , 71, 511-7 | 2.4 | 44 |
| 15 | Higher frequency of allele 2 of the interleukin-1 receptor antagonist gene in patients with juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2001 , 44, 2387-91 | | 41 |
| 14 | Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2016 , 43, 816-24 | 4.1 | 27 |
| 13 | Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1703-10 | 9.5 | 22 |
| 12 | The association between lean mass and bone mineral content in the high disease activity group of adult patients with juvenile idiopathic arthritis. <i>BMC Musculoskeletal Disorders</i> , 2014 , 15, 51 | 2.8 | 9 |
| 11 | Bone status in adults with early-onset juvenile idiopathic arthritis following 1-year anti-TNF β therapy and discontinuation of glucocorticoids. <i>Rheumatology International</i> , 2013 , 33, 2001-7 | 3.6 | 9 |
| 10 | Assessment of effectiveness and safety of biosimilar infliximab (CT-P13) in a real-life setting for treatment of patients with active rheumatoid arthritis or ankylosing spondylitis. <i>Current Medical Research and Opinion</i> , 2018 , 34, 1763-1769 | 2.5 | 8 |
| 9 | Serum sclerostin in high-activity adult patients with juvenile idiopathic arthritis. <i>Arthritis Research and Therapy</i> , 2014 , 16, 460 | 5.7 | 8 |
| 8 | Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate. <i>RMD Open</i> , 2020 , 6, | 5.9 | 5 |
| 7 | OP0289 A Prospective, Randomized, Open-Label, Assessor-Blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids versus Glucocorticoids Alone in Patients with Polymyositis and Dermatomyositis (Prometheus Trial). <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 171.1-171 | 2.4 | 2 |
| 6 | A52: The Impact of Adalimumab on Growth in Patients With Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2014 , 66, S77-S78 | 9.5 | 1 |

- 5 SAT0349 A Tailored Approach to Reduce Dose of Anti-TNF Drugs is Equally Effective, but Substantially Less Costly than Standard Dosing in Patients with Ankylosing Spondylitis over One Year: A Matched Observational Study. *Annals of the Rheumatic Diseases*, **2014**, 73, 719.1-719 2.4 1
- 4 Quantiferon-TB Gold test in screening for latent tuberculosis before and during antitumour necrosis factor treatment. *Arthritis Research and Therapy*, **2007**, 9, P33 5.7 1
- 3 FRI0165 Effectiveness and Safety of Biosimilar Infliximab (CT-P13) in A Real-Life Setting in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis. *Annals of the Rheumatic Diseases*, **2016**, 75, 489.2-489 2.4
- 2 SAT0366 Effect of First-Line Anti-TNF Therapy on Fatigue in Patients with Ankylosing Spondylitis □ Results from the Czech BIOLOGICS Registry Attra. *Annals of the Rheumatic Diseases*, **2014**, 73, 726.1-726 2.4
- 1 THU0168 Monotherapy with Biological Disease-Modifying Anti-Rheumatic Drugs-Data from the Czech Registry Attra. *Annals of the Rheumatic Diseases*, **2014**, 73, 238.2-238 2.4